The Recall Desk
ModerateFDA (Drugs)·D-1271-2019·Announced 2019-05-08

AmEx Pharmacy Recalls Bevacizumab Syringes Due to Defective Delivery System

AmEx Pharmacy is recalling 249 syringes of Bevacizumab intravitreal injection because the delivery system is difficult to express.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: The recall is classified as FDA Class II, and the defect is a mechanical issue (difficult to express) without reported injuries or illnesses, fitting the criteria for a moderate severity recall.

Plain-English summary

Pacifico National, Inc. dba AmEx Pharmacy is recalling 249 syringes of Bevacizumab 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. The product was repackaged by AmEx Pharmacy in Melbourne, Florida, and distributed nationwide in the US.

The recall was initiated because the delivery system is defective and difficult to express. The affected product is identified by Lot 190212AB with a beyond-use date of May 13, 2019.

Consumers and healthcare providers should stop using the affected syringes and contact AmEx Pharmacy for further instructions or a return.

The recalled product

Product
BEVACIZUMAB 1.25 mg/0.05 mL 31G MJ syringe Intravitreal Injection. This biologic product was repackaged by AmEx Pharmacy 1515 Elizabeth St. Suite J Melbourne, FL 32901 Lot:190212AB BUD:5/13/2019, Repackaged on 2/12/2019
Affected units
249

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: 190212AB BUD: 5/13/2019

Distribution

Distributed nationwide across the United States.

Same manufacturer · Pacifico National, Inc. dba AmEx Pharmacy

See all →